Lymphoma classification and the tools of our trade: an introduction to the 2012 USCAP Long Course

Swerdlow, Steven H.

doi:10.1038/modpathol.2012.177

Cited by 34 publications

(17 citation statements)

References 47 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This was a noninferiority study, and there was a high dropout rate in the WBRT arm. Although 2‐year PFS was prolonged with WBRT versus chemotherapy alone (43.5% vs 30.7%), there was no OS difference (32.4 vs 37.1 months) . The neurotoxicity rate was nearly doubled in the radiotherapy group (49% vs 26%).…”

Section: Management Of Newly Diagnosed Pcnslmentioning

confidence: 95%

“…Although 2-year PFS was prolonged with WBRT versus chemotherapy alone (43.5% vs 30.7%), there was no OS difference (32.4 vs 37.1 months). 44,45 The neurotoxicity rate was nearly doubled in the radiotherapy group (49% vs 26%). These findings suggest that omitting WBRT from the initial treatment of PCNSL may not compromise OS and might better preserve neurological function.…”

Section: Chemotherapy and Multimodality Therapymentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis and management of primary central nervous system lymphoma

Han

Batchelor

2017

Cancer

142

147

View full text Add to dashboard Cite

Primary central nervous system lymphoma (PCNSL) is a rare and aggressive extranodal non-Hodgkin lymphoma (NHL) that is confined to the brain, eyes, spinal cord, or leptomeninges without systemic involvement. The overall prognosis, diagnosis, and management of PCNSL differ from those for other types of NHL. Prompt diagnosis and initiation of treatment are vital for improving clinical outcomes. PCNSL is responsive to radiation therapy; however, whole-brain radiotherapy (WBRT) inadequately controls the disease when it is used alone, and its delayed neurotoxicity causes neurocognitive impairment, especially in elderly patients. High-dose methotrexate (HD-MTX)-based induction chemotherapy with or without autologous stem cell transplantation (ASCT) or reduced-dose WBRT leads to durable disease control and less neurotoxicity. The optimal treatment has yet to be defined; however, HD-MTX-based induction chemotherapy is considered standard for newly diagnosed PCNSL. Ongoing randomized trials are addressing the roles of rituximab and consolidative treatment with ASCT or reduced-dose WBRT. Despite high tumor response rates with the initial treatment, many patients relapse with a very poor prognosis. The optimal treatment for refractory or relapsed PCNSL is poorly defined. The choice of salvage treatment depends on a patient's age, previous treatment and response, performance status, and comorbidities at the time of relapse. This review provides an overview of the clinical features, diagnosis, pathology, and management of PCNSL in immunocompetent patients, and it focuses on recent advances in treatment. Cancer 2017;123:4314-24. © 2017 American Cancer Society.

show abstract

Section: Management Of Newly Diagnosed Pcnslmentioning

confidence: 95%

Section: Chemotherapy and Multimodality Therapymentioning

confidence: 99%

Diagnosis and management of primary central nervous system lymphoma

Han

Batchelor

2017

Cancer

142

147

View full text Add to dashboard Cite

show abstract

“…This is especially helpful in distinguishing small cell lymphomas, small clonal populations, and aberrant B‐cell populations with a loss of light‐chain expression . Likewise, expanding numbers of immunohistochemical markers are available for identifying the cell lineage and neoplastic phenotype . For example, cyclin D1 and SOX11 on cell block or cytospin preparations have been shown to be a useful adjunct in diagnosing mantle cell lymphoma .…”

Section: What Has Changed Over the Past 10 Years?mentioning

confidence: 99%

“…17 Likewise, expanding numbers of immunohistochemical markers are available for identifying the cell lineage and neoplastic phenotype. 18 For example, cyclin D1 and SOX11 on cell block or cytospin preparations have been shown to be a useful adjunct in diagnosing mantle cell lymphoma. 19 Standard fluorescence in situ hybridization tests can be used to identify lymphomas with characteristic chromosomal translocations, 9,10,20 including follicular lymphomas (t (14;18)), 7 mantle cell lymphomas (t (11;14)), 6 Burkitt lymphomas (t (8;14)), and anaplastic T-cell lymphomas (t(2;5)).…”

Section: What Can We Learn From the Past?mentioning

confidence: 99%

Evolving role of FNA biopsy in diagnosing lymphoma: Past, present, and future

Caraway

2015

Cancer Cytopathology

View full text Add to dashboard Cite

Despite being challenged more than a decade ago, fine‐needle aspiration biopsy continues to have a valuable role in diagnosing lymphomas. An updated lymphoma classification and several advances in technologies have aided in its increased acceptance and use; however, now is the time to integrate fine‐needle aspiration biopsy with ancillary studies and obtain material for potential molecular testing in the routine workup of lymphomas to ensure its continued use in the future.

show abstract

“…These groups, in turn, consist of multiple distinct clinicopathological entities, such as follicular lymphoma, Burkitt lymphoma, anaplastic large cell lymphoma (ALCL), etc. , based on their immunophenotype, and molecular and clinical features [10]. This current classification also allows for gray-zone or borderline lymphomas with features of both Hodgkin and non-Hodgkin lymphoma (NHL) [11–14].…”

Section: Introductionmentioning

confidence: 99%

Biostable ssDNA Aptamers Specific for Hodgkin Lymphoma

Parekh

Kamble

Zhao

et al. 2013

Sensors

View full text Add to dashboard Cite

As a “chemical antibody”, oligonucleotide aptamers can specifically bind to their target molecules. However, clinical potential of aptamers in disease diagnosis is not yet fully explored. Using a tumor cell-based selection protocol, we developed single-stranded DNA aptamers for Hodgkin lymphoma (HL) tumor cells. The aptamers specifically bound to HL cells with a high affinity, reaching maximal cell binding at 10 nM final concentration. Importantly, the aptamers were able to selectively detect HL cells and did not react to other tumor or blood cells in mixed samples, indicating that the aptamers can be used as a specific probe for in vitro analysis of HL cells. Moreover, due to the inherent properties of DNA, the aptamers were stable in human serum, suggesting potential for in vivo detection of HL tumor cells.

show abstract

Lymphoma classification and the tools of our trade: an introduction to the 2012 USCAP Long Course

Cited by 34 publications

References 47 publications

Diagnosis and management of primary central nervous system lymphoma

Diagnosis and management of primary central nervous system lymphoma

Evolving role of FNA biopsy in diagnosing lymphoma: Past, present, and future

Biostable ssDNA Aptamers Specific for Hodgkin Lymphoma

Contact Info

Product

Resources

About